Cell Type Classification Via Deep Learning On Single-Cell Gene Expression Data

Single-cell sequencing is a recently advanced revolutionary technology which enables researchers to obtain genomic, transcriptomic, or multi-omics information through gene expression analysis. It gives the advantage of analyzing highly heterogenous cell type information compared to traditional sequencing methods, which is gaining popularity in the biomedical area. Moreover, this analysis can help for early diagnosis and drug development of tumor cells, and cancer cell types. In the workflow of gene expression data profiling, identification of the cell types is an important task, but it faces many challenges like the curse of dimensionality, sparsity, batch effect, and overfitting. However, these challenges can be overcome by performing a feature selection technique which selects more relevant features by reducing feature dimensions. In this research work, recurrent neural network-based feature selection model is proposed to extract relevant features from high dimensional, and low sample size data. Moreover, a deep learning-based gene embedding model is also proposed to reduce data sparsity of single-cell data for cell type identification. The proposed frameworks have been implemented with different architectures of recurrent neural networks, and demonstrated via real-world micro-array datasets and single-cell RNA-seq data and observed that the proposed models perform better than other feature selection models. A semi-supervised model is also implemented using the same workflow of gene embedding concept since labeling data is very cumbersome, time consuming, and requires manual effort and expertise in the field. Therefore, different ratios of labeled data are used in the experiment to validate the concept. Experimental results show that the proposed semi-supervised approach represents very encouraging performance even though a limited number of labeled data is used via the gene embedding concept. In addition, graph attention based autoencoder model has also been studied to learn the latent features by incorporating prior knowledge with gene expression data for cell type classification. Index Terms — Single-Cell Gene Expression Data, Gene Embedding, Semi-Supervised model, Incorporate Prior Knowledge, Gene-gene Interaction Network, Deep Learning, Graph Auto Encode

Machine Learning and Integrative Analysis of Biomedical Big Data.

Recent developments in high-throughput technologies have accelerated the accumulation of massive amounts of omics data from multiple sources: genome, epigenome, transcriptome, proteome, metabolome, etc. Traditionally, data from each source (e.g., genome) is analyzed in isolation using statistical and machine learning (ML) methods. Integrative analysis of multi-omics and clinical data is key to new biomedical discoveries and advancements in precision medicine. However, data integration poses new computational challenges as well as exacerbates the ones associated with single-omics studies. Specialized computational approaches are required to effectively and efficiently perform integrative analysis of biomedical data acquired from diverse modalities. In this review, we discuss state-of-the-art ML-based approaches for tackling five specific computational challenges associated with integrative analysis: curse of dimensionality, data heterogeneity, missing data, class imbalance and scalability issues

High-throughput and computational approaches for diagnostic and prognostic host tuberculosis biomarkers

High-throughput techniques strive to identify new biomarkers that will be useful for the diagnosis, treatment, and prevention of tuberculosis (TB). However, their analysis and interpretation pose considerable challenges. Recent developments in the high-throughput detection of host biomarkers in TB are reported in this review

Pathway-Based Multi-Omics Data Integration for Breast Cancer Diagnosis and Prognosis.

Ph.D. Thesis. University of Hawaiʻi at Mānoa 2017

Morphological Profiling for Drug Discovery in the Era of Deep Learning

Morphological profiling is a valuable tool in phenotypic drug discovery. The advent of high-throughput automated imaging has enabled the capturing of a wide range of morphological features of cells or organisms in response to perturbations at the single-cell resolution. Concurrently, significant advances in machine learning and deep learning, especially in computer vision, have led to substantial improvements in analyzing large-scale high-content images at high-throughput. These efforts have facilitated understanding of compound mechanism-of-action (MOA), drug repurposing, characterization of cell morphodynamics under perturbation, and ultimately contributing to the development of novel therapeutics. In this review, we provide a comprehensive overview of the recent advances in the field of morphological profiling. We summarize the image profiling analysis workflow, survey a broad spectrum of analysis strategies encompassing feature engineering- and deep learning-based approaches, and introduce publicly available benchmark datasets. We place a particular emphasis on the application of deep learning in this pipeline, covering cell segmentation, image representation learning, and multimodal learning. Additionally, we illuminate the application of morphological profiling in phenotypic drug discovery and highlight potential challenges and opportunities in this field.Comment: 44 pages, 5 figure, 5 table

Defining a robust biological prior from Pathway Analysis to drive Network Inference

Inferring genetic networks from gene expression data is one of the most challenging work in the post-genomic era, partly due to the vast space of possible networks and the relatively small amount of data available. In this field, Gaussian Graphical Model (GGM) provides a convenient framework for the discovery of biological networks. In this paper, we propose an original approach for inferring gene regulation networks using a robust biological prior on their structure in order to limit the set of candidate networks. Pathways, that represent biological knowledge on the regulatory networks, will be used as an informative prior knowledge to drive Network Inference. This approach is based on the selection of a relevant set of genes, called the "molecular signature", associated with a condition of interest (for instance, the genes involved in disease development). In this context, differential expression analysis is a well established strategy. However outcome signatures are often not consistent and show little overlap between studies. Thus, we will dedicate the first part of our work to the improvement of the standard process of biomarker identification to guarantee the robustness and reproducibility of the molecular signature. Our approach enables to compare the networks inferred between two conditions of interest (for instance case and control networks) and help along the biological interpretation of results. Thus it allows to identify differential regulations that occur in these conditions. We illustrate the proposed approach by applying our method to a study of breast cancer's response to treatment

MACHINE LEARNING AND DEEP LEARNING APPROACHES FOR GENE REGULATORY NETWORK INFERENCE IN PLANT SPECIES

The construction of gene regulatory networks (GRNs) is vital for understanding the regulation of metabolic pathways, biological processes, and complex traits during plant growth and responses to environmental cues and stresses. The increasing availability of public databases has facilitated the development of numerous methods for inferring gene regulatory relationships between transcription factors and their targets. However, there is limited research on supervised learning techniques that utilize available regulatory relationships of plant species in public databases. This study investigates the potential of machine learning (ML), deep learning (DL), and hybrid approaches for constructing GRNs in plant species, specifically Arabidopsis thaliana, poplar, and maize. Challenges arise due to limited training data for gene regulatory pairs, especially in less-studied species such as poplar and maize. Nonetheless, our results demonstrate that hybrid models integrating ML and artificial neural network (ANN) techniques significantly outperformed traditional methods in predicting gene regulatory relationships. The best-performing hybrid models achieved over 95% accuracy on holdout test datasets, surpassing traditional ML and ANN models and also showed good accuracy on lignin biosynthesis pathway analysis. Employing transfer learning techniques, this study has also successfully transferred the known knowledge of gene regulation from one species to another, substantially improving performance and manifesting the viability of cross-species learning using deep learning-based approaches. This study contributes to the methodology for growing body of knowledge in GRN prediction and construction for plant species, highlighting the value of adopting hybrid models and transfer learning techniques. This study and the results will help to pave a way for future research on how to learn from known to unknown and will be conductive to the advance of modern genomics and bioinformatics

Transcriptomic data integration for precision medicine in leukemia

This thesis is comprised of three studies demonstrating the application of different statistical and bioinformatic approaches to address distinct challenges of implementing precision medicine strategies for hematological malignancies. The approaches focus on the analysis of next-generation sequencing data, including both genomic and transcriptomics, to deconvolute disease biology and underlying mechanisms of drug sensitivities and resistance. The outcomes of the studies have clinical implications for advancing current diagnosis and treatment paradigms in patients with hematological diseases. Study I, RNA sequencing has not been widely adopted in a clinical diagnostic setting due to continuous development and lack of standardization. Here, the aim was to evaluate the efficiency of two different RNA-seq library preparation protocols applied to cells collected from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. The poly-A-tailed mRNA selection (PA) and ribo- depletion (RD) based RNA-seq library preparation protocols were compared and evaluated for detection of gene fusions, variant calling and gene expression profiling. Overall, both protocols produced broadly consistent results and similar outcomes. However, the PA protocol was more efficient in quantifying expression of leukemia marker genes and drug targets. It also provided higher sensitivity and specificity for expression-based classification of leukemia. In contrast, the RD protocol was more suitable for gene fusion detection and captured a greater number of transcripts. Importantly, high technical variations were observed in samples from two leukemia patient cases suggesting further development of strategies for transcriptomic quantification and data analysis. Study II, the BCL-2 inhibitor venetoclax is an approved and effective agent in combination with hypomethylating agents or low dose cytarabine for AML patients, unfit for intensive induction chemotherapy. However, a limited number of patients responding to venetoclax and development of resistance to the treatment presents a challenge for using the drug to benefit the majority of the AML patients. The aim was to investigate genomic and transcriptomic biomarkers for venetoclax sensitivity and enable identification of the patients who are most responsive to venetoclax treatment. We found that venetoclax sensitive samples are enriched with WT1 and IDH1/IDH2 mutations. Intriguingly, HOX family genes, including HOXB9, HOXA5, HOXB3, HOXB4, were found to be significantly overexpressed in venetoclax sensitive patients. Thus, these HOX-cluster genes expression biomarkers can be explored in a clinical trial setting to stratify AML patients responding to venetoclax based therapies. Study III, venetoclax treatment does not benefit all AML patients that demands identifying biomarkers to exclude the patients from venetoclax based therapies. The aim was to investigate transcriptomic biomarkers for ex vivo venetoclax resistance in AML patients. The correlation of ex vivo venetoclax response with gene expression profiles using a machine learning approach revealed significant overexpression of S100 family genes, S100A8 and S100A9. Moreover, high expression ofS100A9was found to be associated with birabresib (BET inhibitor) sensitivity. The overexpression of S100A8 and S100A9 could potentially be used to detect and monitor venetoclax resistance. The combination of BCL-2 and BET inhibitors may sensitize AML cells to venetoclax upon BET inhibition and block leukemic cell survival.In this thesis, the aim was to utilize gene expression information for advanced precision medicine outcomes in patients with hematological malignancies. In the study, I, the contemporary mainstream library preparation protocols, Ribo-depletion and PolyA enrichment used for RNA sequencing, were compared in order to select the protocol that suffices the goal of the experiment, especially in patients with acute leukemias. In study II, we applied bioinformatics approaches to identify IDH1/2 mutation and HOX family gene expression correlated with ex vivo sensitivity to BCL-2 inhibitor venetoclax in acute myeloid leukemia (AML) patients. In study III, statistical and machine learning methods were implemented to identify S100A8/A9 gene expression biomarkers for ex vivo resistance to venetoclax in AML patients. In summary, this thesis addresses the challenges of utilizing gene expression information to stratify patients based on biomarkers to promote precision medicine practice in hematological malignancies